Home>>Signaling Pathways>> Immunology/Inflammation>> Reactive Oxygen Species>>Iron sucrose

Iron sucrose

Catalog No.GC39600

Iron sucrose (Iron saccharate) is a intravenous iron preparation and a pro-oxidant agent.

Products are for research use only. Not for human use. We do not sell to patients.

Iron sucrose Chemical Structure

Cas No.: 8047-67-4

Size Price Stock Qty
25mg
$19.00
In stock
100mg
$46.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Iron sucrose (Iron saccharate) is a intravenous iron preparation and a pro-oxidant agent. Iron sucrose has the potential for iron deficiency anemia treatment[1][2][3][4].

[1]. Kristiyana Kaneva, et al. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262. [2]. Kristin E Brandt, et al. Augmentation of Intracellular Iron Using Iron Sucrose Enhances the Toxicity of Pharmacological Ascorbate in Colon Cancer Cells. Redox Biol. 2018 Apr;14:82-87. [3]. Ko-Lin Kuo, et al. Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD. J Am Soc Nephrol. 2014 Nov;25(11):2596-606. [4]. Richard A Zager, et al. Combined Iron Sucrose and Protoporphyrin Treatment Protects Against Ischemic and Toxin-Mediated Acute Renal Failure. Kidney Int. 2016 Jul;90(1):67-76.

Reviews

Review for Iron sucrose

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Iron sucrose

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.